SABA, Vittorio
 Distribuzione geografica
Continente #
NA - Nord America 2.556
EU - Europa 1.382
AS - Asia 372
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 4.317
Nazione #
US - Stati Uniti d'America 2.547
UA - Ucraina 393
SE - Svezia 229
IE - Irlanda 195
TR - Turchia 193
DE - Germania 161
DK - Danimarca 151
IT - Italia 127
FI - Finlandia 85
KR - Corea 80
SG - Singapore 57
CN - Cina 36
GB - Regno Unito 21
CA - Canada 8
RO - Romania 6
BE - Belgio 5
BG - Bulgaria 4
CL - Cile 4
FR - Francia 4
IR - Iran 3
EU - Europa 2
IN - India 2
CR - Costa Rica 1
IL - Israele 1
NZ - Nuova Zelanda 1
RU - Federazione Russa 1
Totale 4.317
Città #
Jacksonville 395
Chandler 350
Fairfield 251
Dublin 195
Wilmington 142
Ashburn 131
Woodbridge 120
New York 106
Boardman 104
Houston 104
Seattle 90
Lawrence 79
Princeton 79
San Mateo 79
Ann Arbor 69
Cambridge 69
Turin 44
San Diego 20
Des Moines 19
Beijing 13
Izmir 10
Buffalo 7
Falls Church 7
Helsinki 6
London 6
Norwalk 6
Brussels 5
Kilburn 5
Los Angeles 5
Ottawa 4
Palermo 4
Shanghai 4
Venice 4
Campobasso 3
San Jose 3
Wuhan 3
Dallas 2
Foligno 2
Marche 2
Montemarciano 2
North Bergen 2
Pune 2
Redmond 2
Serra 2
Simi Valley 2
Washington 2
'Omer 1
Auburn Hills 1
Auckland 1
Chiswick 1
East Los Angeles 1
Fayetteville 1
Fort Worth 1
Guangzhou 1
Hangzhou 1
Heze 1
Hull 1
Jiaxing 1
Kunshan 1
La Canada Flintridge 1
Las Vegas 1
Montesilvano 1
Montréal 1
Moscow 1
Ozzano Monferrato 1
Pesaro 1
Porto 1
Pozzuoli 1
Red Deer 1
Regina 1
Riva 1
San José 1
Seoul 1
Silver Spring 1
Tehran 1
Varallo Pombia 1
Wuxi 1
Zibo 1
Totale 2.593
Nome #
BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci. 123
Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock 82
Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides 79
Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models. 78
Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model. 76
Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. 74
Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis. 71
Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. 70
Antiendotoxin activity of antimicrobial peptides and glycopeptides. 70
Attività ed espressione della ossido-nitrico sintetasi nella vescica di ratti sottoposti a neuromodulazione sacrale 69
Amphibian Peptides Prevent Endotoxemia and Bacterial Translocation in Bile Duct-Ligated Rats 67
Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria. 67
Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock 67
RNAIII-Inhibiting Peptide-Loaded Polymethylmethacrylate Prevents In Vivo Staphylococcus aureus Biofilm Formation 66
Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. 64
Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. 64
Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. 64
Activity and expression of nitric oxide synthase in rat bladder after sacral neuromodulation 64
Antiseptic compounds still active against bacterial strains isolated from surgical wound infections despite increasing antibiotic resistance. 64
Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock 64
Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats. 63
Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection. 63
Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock 62
Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide 62
Glyoxalase II and glutathione levels in rat liver mitochondria during cold storage in Euro-Collins and University of Wisconsin solutions 61
The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 61
RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 60
Efficacy of quinupristin/dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides. 59
Comparative efficacy of quinupristin/dalfopristin, linezolid, vancomycin and ciprofloxacin in the treatment of experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique 58
Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide 58
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. 58
Effect of mono-dose intraperitoneal cecropins in experimental septic shock 58
LL-37 protects rats against lethal gram-negative sepsis. 57
Treatment of Staphylococcus aureus Biofilm infection by the quorum sensing inhibitor RIP 57
Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with Staphylococcus epidermidis with intermediate resistance to glycopeptides. 57
Experimental study on the efficacy of combination of alpha-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. 56
Cationic peptides combined with betalactams reduce mortality from peritonitis in experimental rat model. 56
A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. 56
Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. 55
The lipopeptides Pal-Lys-Lys-NH(2) and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection 54
Potential therapeutic role of cationic peptides in three experimental models of septic shock 53
The bovine antimicrobial peptide BMAP-28 reduces lethality due to bacterial cell wall components in mouse models of staphylococcal sepsis 53
Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to multiresistant Pseudomonas aeruginosa strain 52
[Vascular graft infection by Staphylococcus epidermidis: efficacy of various perioperative prophylaxis protocols in an animal model]. 52
Polycationic peptides as prophylactic agents against methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis vascular graft infection 52
Mupirocin as prophylactic agent against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate Staphylococcus epidermidis vascular graft infection. 51
RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. 51
Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. 51
Prophylaxis against Staphylococcus aureus vascular graft infection with mupirocin-soaked, collagen-sealed dacron. 51
Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. 50
Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. 50
Single-dose intraperitoneal magainins improve survival in a gram-negative-pathogen septic shock rat model. 50
RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis. 50
Potential therapeutic role of histatins derivative P-113D in experimental rat models of Pseudomonas sepsis 49
Efficacy of rifampin-levofloxacin as a prophylactic agent in preventing Staphylococcus epidermidis graft infection. 49
The cathelicidin-derived tritrpticin enhances the efficacy of ertapenem in experimental rat models of septic shock 49
Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock 49
Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia. 48
Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides. 48
RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. 48
RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. 46
Valore prognostico dell'indice Apache II nell'impiego routinario preoperatorio in chirurgia generale maggiore 46
Therapeutic efficacy of the magainin analog MSI-78 in different intra-abdominal sepsis rat models 45
Efficacy of Tachyplesin III, Colistin and Imipenem against Multiresistant Pseudomonas aeruginosa 45
RNA III Inhibiting Peptide (RIP) inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus 44
Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection. 43
Temporin A as a prophylactic agent against methicillin sodium-susceptible and methicillin sodium-resistant Staphylococcus epidermidis vascular graft infection. 42
Polycationic peptides as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis vascular graft infection. 42
Temporin A Soaking in Combination with Intraperitoneal Linezolid Prevents Vascular Graft Infection in a Subcutaneous Rat Pouch Model Infected with Staphylococcus epidermidis with Intermediate Resistance to Glycopeptides 42
RNAIII inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated S. aureus infections 41
Single-dose intraperitoneal magainins improve survival in a gram-negative pathogens septic shock rat model. 41
Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis. 41
Temporin A as prophylactic agent against methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis vascular graft infection. 40
Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. 40
Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis. 40
Interaction of antimicrobial peptide temporin L with lipopolisaccharide in vitro and in experimental rat models of Gram-negative septic shock. 39
RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine models of staphylococcal sepsis 39
Temporin A alone and in combination with imipenem reduces lethality in mouse models of staphylococcal sepsis 33
Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides 32
Totale 4.401
Categoria #
all - tutte 21.148
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.148


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201910 0 0 0 0 0 0 0 0 0 0 0 10
2019/2020448 2 0 80 1 79 0 78 1 80 5 6 116
2020/20211.096 64 119 153 16 120 88 104 74 114 91 104 49
2021/2022583 51 122 0 27 3 54 15 30 35 92 24 130
2022/20231.040 106 114 91 81 91 106 0 50 286 7 84 24
2023/2024503 109 12 22 88 89 122 5 5 3 4 13 31
Totale 4.401